Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
JAGX Stock Forecast 2026-2027
$2.41
Current Price
$11.37M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to JAGX Price Targets
+10,792.1%
To High Target of $262.50
+10,792.1%
To Median Target of $262.50
+10,792.1%
To Low Target of $262.50
JAGX Price Momentum
-14.2%
1 Week Change
-12.4%
1 Month Change
-97.4%
1 Year Change
-92.6%
Year-to-Date Change
-97.5%
From 52W High of $97.65
+13.7%
From 52W Low of $2.12
📊 TOP ANALYST CALLS
Did JAGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Jaguar Health is one of their latest high-conviction picks.
Latest JAGX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, JAGX has a bullish consensus with a median price target of $262.50 (ranging from $262.50 to $262.50). The overall analyst rating is N/A (N/A/10). Currently trading at $2.41, the median forecast implies a 10,792.1% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JAGX Analyst Ratings
1
Buy
0
Hold
0
Sell
JAGX Price Target Range
Low
$262.50
Average
$262.50
High
$262.50
Current: $2.41
Latest JAGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JAGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | First Berlin | Christian Orquera | Buy | Initiates | $60.00 |
| Jul 7, 2021 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $5.00 |
| Nov 25, 2020 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Nov 25, 2020 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Nov 25, 2020 | Aegis Capital | Buy | Initiates | $N/A | |
| Nov 18, 2019 | H.C. Wainwright | Buy | Reiterates | $N/A | |
| Nov 18, 2019 | HC Wainwright & Co. | Buy | Reiterates | $3.00 | |
| Sep 12, 2019 | Ladenburg Thalmann | Buy | Initiates | $N/A | |
| Jul 11, 2017 | Rodman & Renshaw | Buy | Initiates | $N/A | |
| Nov 12, 2015 | Aegis Capital | Buy | Initiates | $N/A |
Jaguar Health, Inc. (JAGX) Competitors
The following stocks are similar to Jaguar Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
JAGX
Jaguar Health
mkt cap
13.54M
Jaguar Health, Inc. (JAGX) Financial Data
Jaguar Health, Inc. has a market capitalization of $11.37M with a P/E ratio of 0.0x. The company generates $29.57M in trailing twelve-month revenue with a -115.4% profit margin.
Revenue growth is +815.6% quarter-over-quarter, while maintaining an operating margin of +50.2% and return on equity of +286.7%.
Valuation Metrics
Market Cap
$11.37M
Enterprise Value
$36.53M
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
+815.6%
Gross Margin
+94.3%
Operating Margin
+50.2%
Net Margin
-115.4%
EPS Growth
+814.5%
Financial Health
Cash/Price Ratio
+500.7%
Current Ratio
0.6x
Debt/Equity
-2.2x
ROE
+286.7%
ROA
-35.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Jaguar Health, Inc. (JAGX) Business Model
About Jaguar Health, Inc.
What They Do
Develops plant-based medicines for gastrointestinal distress.
Business Model
Jaguar Health, Inc. operates through two segments: Animal Health and Human Health. The company generates revenue by developing and commercializing prescription medications for gastrointestinal issues in both humans and companion animals, with key products targeting specific ailments such as diarrhea related to HIV/AIDS and chemotherapy in dogs.
Additional Information
The company is advancing multiple products through various stages of clinical trials, including Crofelemer for adult cancer patients and NP-300 for moderate-to-severe diarrhea. Jaguar Health is headquartered in San Francisco, California, and aims to address unmet needs in gastrointestinal health for both human and veterinary markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
47
CEO
Ms. Lisa A. Conte
Country
United States
IPO Year
2015
Website
jaguar.healthJaguar Health, Inc. (JAGX) Latest News & Analysis
Latest News
Quick Summary
Jaguar Health's Napo Pharmaceuticals presented positive results on crofelemer for pediatric intestinal failure at the ESPGHAN Meeting, showing up to 48% reduction in parenteral support in MVID patients.
Why It Matters
Jaguar Health's advancements in crofelemer for rare intestinal failure diseases could enhance its market position and revenue potential, influencing investor sentiment positively.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Jaguar Health is advancing its global development of crofelemer for rare intestinal diseases, with presentations scheduled for June 2026. The company also initiated the conversion of its Series O Preferred Stock.
Why It Matters
Jaguar Health's focus on crofelemer for rare diseases and upcoming presentations could indicate potential growth and value, impacting investor sentiment and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Jaguar Health announced positive results from a study on crofelemer for treating chemotherapy-induced diarrhea in dogs. The company has submitted a New Animal Drug Application for full FDA approval.
Why It Matters
Jaguar's successful study and NADA submission for crofelemer may lead to full FDA approval, potentially boosting sales and market position in the veterinary pharmaceutical sector.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Jaguar Health, Inc. (NASDAQ:JAGX) is exploring strategic alternatives to maximize stockholder value, including potential mergers or partnerships, as it prepares to file a New Drug Application for crofelemer.
Why It Matters
Jaguar Health is exploring strategic alternatives to enhance shareholder value, coinciding with its NDA filing for crofelemer, which could attract investment interest and impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Jaguar Health's joint venture, Magdalena Biosciences, reported preclinical results showing that a coca leaf extract prevented weight gain in mice on a high-fat diet, supporting its potential as a weight loss treatment.
Why It Matters
The preclinical study suggests potential for a new weight loss treatment, which could drive Jaguar Health's stock value and attract investor interest in innovative therapies.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Jaguar Health, Inc. (NASDAQ:JAGX) will present at the Life Sciences Virtual Investor Forum on June 24, 2026. CEO Lisa Conte will discuss developments in pediatric intestinal failure treatments.
Why It Matters
Jaguar Health's presentations on key pediatric conditions may influence stock performance and investor sentiment, highlighting potential growth opportunities in niche markets.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About JAGX Stock
What is Jaguar Health, Inc.'s (JAGX) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Jaguar Health, Inc. (JAGX) has a median price target of $262.50. The highest price target is $262.50 and the lowest is $262.50.
Is JAGX stock a good investment in 2027?
According to current analyst ratings, JAGX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JAGX stock?
Wall Street analysts predict JAGX stock could reach $262.50 in the next 12 months. This represents a 10,792.1% increase from the current price of $2.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Jaguar Health, Inc.'s business model?
Jaguar Health, Inc. operates through two segments: Animal Health and Human Health. The company generates revenue by developing and commercializing prescription medications for gastrointestinal issues in both humans and companion animals, with key products targeting specific ailments such as diarrhea related to HIV/AIDS and chemotherapy in dogs.
What is the highest forecasted price for JAGX Jaguar Health, Inc.?
The highest price target for JAGX is $262.50 from at , which represents a 10,792.1% increase from the current price of $2.41.
What is the lowest forecasted price for JAGX Jaguar Health, Inc.?
The lowest price target for JAGX is $262.50 from at , which represents a 10,792.1% increase from the current price of $2.41.
What is the overall JAGX consensus from analysts for Jaguar Health, Inc.?
The overall analyst consensus for JAGX is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $262.50.
How accurate are JAGX stock price projections?
Stock price projections, including those for Jaguar Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 9:26 PM UTC